Comparison of total parathyroidectomy without autotransplantation and without thymectomy versus total parathyroidectomy with autotransplantation and with thymectomy for secondary hyperparathyroidism: TOPAR PILOT-Trial

Katja Schlosser, Johannes A Veit, Stefan Witte, Emilio Domínguez Fernández, Norbert Victor, Hans-Peter Knaebel, Christoph M Seiler, Matthias Rothmund, Katja Schlosser, Johannes A Veit, Stefan Witte, Emilio Domínguez Fernández, Norbert Victor, Hans-Peter Knaebel, Christoph M Seiler, Matthias Rothmund

Abstract

Background: Secondary hyperparathyroidism (sHPT) is common in patients with chronic renal failure. Despite the initiation of new therapeutic agents, several patients will require parathyroidectomy (PTX). Total PTX with autotransplantation of parathyroid tissue (TPTX+AT) and subtotal parathyroidectomy (SPTX) are currently considered as standard surgical procedures in the treatment of sHPT. Recurrencerates after TPTX+AT or SPTX are between 10% and 12% (median follow up: 36 months). Recent retrospective studies demonstrated a lower rate of recurrent sHPT of 0-4% after PTX without autotransplantation and thymectomy (TPTX) with no higher morbidity when compared to the standard procedures. The observed superiority of TPTX is flawed due to different definitions of outcomes, varying follow up periods and different surgical treatment strategies (with and without thymectomy).

Methods/design: Patients with sHPT (intact parathyroid hormone > 10 times above the upper limit of normal) on long term dialysis (>12 months) will be randomized either to TPTX or TPTX+AT and followed for 36 months. Outcome parameters are recurrence rates of sHPT, frequencies of reoperations due to refractory hypoparathyroidism or recurrent/persistent hyperparathyroidism, postoperative morbidity and mortality and quality of life. 50 patients per group will be randomized in order to obtain relevant frequencies of outcome parameters that will form the basis for a large scale confirmatory multicentred randomized controlled trial.

Discussion: sHPT is a disease with a high incidence in patients with chronic renal failure. Even a small difference in outcomes will be of clinical relevance. To assess sufficient data about the rate of recurrent sHPT after both methods, a multicentred, randomized controlled trial (MRCT) under standardized conditions is mandatory. Due to the existing uncertainties the calculated number of patients necessary in each treatment arm (n > 4000) makes it impossible to perform this study as a confirmatory trial. Therefore estimates of different outcomes are performed using a pilot MRCT comparing 50 versus 50 randomized patients in order to establish a hypothesis that can be tested thereafter. If TPTX proves to have a lower rate of recurrent sHPT, no relevant disadvantages and no higher morbidity than TPTX+AT, current surgical practice may be changed.

Trial registration: International Standard Randomized Controlled Trial Number Registration (ISRCTN86202793).

Figures

Figure 1
Figure 1
This figure shows the enlargement of a parathyroid autograft in a patient with recurrent secondary hyperparathyroidism, demonstrated by a knob underneath the scar.
Figure 2
Figure 2
This figure represents a flowchart comprising all the interventions of the TOPAR PILOT trial.

References

    1. Salem MM. Hyperparathyroidism in the hemodialysis population: a survey of 612 patients. Am J Kidney Dis. 1997;29:862–865.
    1. Owda A, Elhwairis H, Narra S, Towery H, Osama S. Secondary hyperparathyroidism in chronic hemodialysis patients: prevalence and race. Ren Fail. 2003;25:595–602. doi: 10.1081/JDI-120022551.
    1. U F, HJ SH. Summary of the Annual Report on Dialysis Treatment and Renal Transplantation in Germany for 2005 / 2006. QuaSi- Niere. 2006;14:1085–1090.
    1. K/DOQI Clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45:S1–153.
    1. Silver J, Levi R. Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease. Kidney Int Suppl. 2005:S8–12. doi: 10.1111/j.1523-1755.2005.09501.x.
    1. Slatopolsky E, Dusso A, Brown AJ. The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure. Am J Med Sci. 1999;317:370–376. doi: 10.1097/00000441-199906000-00004.
    1. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl. 1999;73:S14–S19. doi: 10.1046/j.1523-1755.1999.07304.x.
    1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607–617.
    1. Ribeiro S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, Remedio F, Ribeiro F. Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant. 1998;13:2037–2040. doi: 10.1093/ndt/13.8.2037.
    1. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483. doi: 10.1056/NEJM200005183422003.
    1. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol. 2002;39:695–701. doi: 10.1016/S0735-1097(01)01781-8.
    1. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis. 2000;35:1226–1237.
    1. Johnson CA, McCarthy J, Bailie GR, Deane J, Smith S. Analysis of renal bone disease treatment in dialysis patients. Am J Kidney Dis. 2002;39:1270–1277. doi: 10.1053/ajkd.2002.33401.
    1. Indridason OS, Quarles LD. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int. 2000;57:282–292. doi: 10.1046/j.1523-1755.2000.00819.x.
    1. Maung HM, Elangovan L, Frazao JM, Bower JD, Kelley BJ, Acchiardo SR, Rodriguez HJ, Norris KC, Sigala JF, Rutkowski M, Robertson JA, Goodman WG, Levine BS, Chesney RW, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis. 2001;37:532–543.
    1. Wada M, Nagano N, Nemeth EF. The calcium receptor and calcimimetics. Curr Opin Nephrol Hypertens. 1999;8:429–433. doi: 10.1097/00041552-199907000-00006.
    1. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, bu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516–1525. doi: 10.1056/NEJMoa031633.
    1. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int. 1999;55:299–307. doi: 10.1046/j.1523-1755.1999.00240.x.
    1. Slatopolsky E, Dusso A, Brown A. New analogs of vitamin D3. Kidney Int Suppl. 1999;73:S46–S51. doi: 10.1046/j.1523-1755.1999.07305.x.
    1. Martin KJ, Gonzalez EA, Gellens ME, Hamm LL, Abboud H, Lindberg J. Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2. Am J Kidney Dis. 1998;32:S61–S66.
    1. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol. 1998;9:1427–1432.
    1. Hirata M, Katsumata K, Masaki T, Koike N, Endo K, Tsunemi K, Ohkawa H, Kurokawa K, Fukagawa M. 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis. Kidney Int. 1999;56:2040–2047. doi: 10.1046/j.1523-1755.1999.00772.x.
    1. Malberti F, Marcelli D, Conte F, Limido A, Spotti D, Locatelli F. Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study. J Am Soc Nephrol. 2001;12:1242–1248.
    1. Tominaga Y, Uchida K, Haba T, Katayama A, Sato T, Hibi Y, Numano M, Tanaka Y, Inagaki H, Watanabe I, Hachisuka T, Takagi H. More than 1,000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism. Am J Kidney Dis. 2001;38:S168–S171.
    1. Fassbinder W, Brunner FP, Brynger H, Ehrich JH, Geerlings W, Raine AE, Rizzoni G, Selwood NH, Tufveson G, Wing AJ. Combined report on regular dialysis and transplantation in Europe, XX, 1989. Nephrol Dial Transplant. 1991;6 Suppl 1:5–35.
    1. Stanbury SW, Lumb GA, Nicholson WF. Elective subtotal parathyroidectomy for renal hyperparathyroidism. Lancet. 1960;1:793–799. doi: 10.1016/S0140-6736(60)90678-4.
    1. Wilson RE, Hampers CL, Bernstein DS, Johnson JW, Merrill JP. Subtotal parathyroidectomy in chronic renal failure: a seven-year experience in a dialysis and transplant program. Ann Surg. 1971;174:640–654.
    1. Richards ML, Wormuth J, Bingener J, Sirinek K. Parathyroidectomy in secondary hyperparathyroidism: Is there an optimal operative management? Surgery. 2006;139:174–180. doi: 10.1016/j.surg.2005.08.036.
    1. Rothmund M, Wagner PK, Schark C. Subtotal parathyroidectomy versus total parathyroidectomy and autotransplantation in secondary hyperparathyroidism: a randomized trial. World J Surg. 1991;15:745–750. doi: 10.1007/BF01665309.
    1. Drueke TB, Zingraff J. The dilemma of parathyroidectomy in chronic renal failure. Curr Opin Nephrol Hypertens. 1994;3:386–395. doi: 10.1097/00041552-199407000-00004.
    1. Kinnaert P, Salmon I, coster-Gervy C, Vienne A, De PL, Hooghe L, Tielemans C. Long-term results of subcutaneous parathyroid grafts in uremic patients. Arch Surg. 2000;135:186–190. doi: 10.1001/archsurg.135.2.186.
    1. Ockert S, Willeke F, Richter A, Jonescheit J, Schnuelle P, Van Der WF, Post S. Total parathyroidectomy without autotransplantation as a standard procedure in the treatment of secondary hyperparathyroidism. Langenbecks Arch Surg. 2002;387:204–209. doi: 10.1007/s00423-002-0307-9.
    1. Lorenz K, Ukkat J, Sekulla C, Gimm O, Brauckhoff M, Dralle H. Total parathyroidectomy without autotransplantation for renal hyperparathyroidism: experience with a qPTH-controlled protocol. World J Surg. 2006;30:743–751. doi: 10.1007/s00268-005-0379-0.
    1. Ogg CS. Total parathyroidectomy in treatment of secondary (renal) hyperparathyroidism. Br Med J. 1967;4:331–334.
    1. Stracke S, Jehle PM, Sturm D, Schoenberg MH, Widmaier U, Beger HG, Keller F. Clinical course after total parathyroidectomy without autotransplantation in patients with end-stage renal failure. Am J Kidney Dis. 1999;33:304–311.
    1. Nicholson ML, Veitch PS, Feehally J. Parathyroidectomy in chronic renal failure: comparison of three operative strategies. J R Coll Surg Edinb. 1996;41:382–387.
    1. Hampl H, Steinmuller T, Stabell U, Klingenberg HJ, Schnoy N, Neuhaus P. Recurrent hyperparathyroidism after total parathyroidectomy and autotransplantation in patients with long-term hemodialysis. Miner Electrolyte Metab. 1991;17:256–260.
    1. Skinner KA, Zuckerbraun L. Recurrent secondary hyperparathyroidism. An argument for total parathyroidectomy. Arch Surg. 1996;131:724–727.
    1. Tominaga Y, Numano M, Tanaka Y, Uchida K, Takagi H. Surgical treatment of renal hyperparathyroidism. Semin Surg Oncol. 1997;13:87–96. doi: 10.1002/(SICI)1098-2388(199703/04)13:2<87::AID-SSU4>;2-Y.
    1. Henry JF, Denizot A, Audiffret J, France G. Results of reoperations for persistent or recurrent secondary hyperparathyroidism in hemodialysis patients. World J Surg. 1990;14:303–306. doi: 10.1007/BF01658510.
    1. Kinnaert P, Nagy N, coster-Gervy C, De PL, Salmon I, Vereerstraeten P. Persistent hyperparathyroidism requiring surgical treatment after kidney transplantation. World J Surg. 2000;24:1391–1395. doi: 10.1007/s002680010230.
    1. Hargrove GM, Pasieka JL, Hanley DA, Murphy MB. Short- and long-term outcome of total parathyroidectomy with immediate autografting versus subtotal parathyroidectomy in patients with end-stage renal disease. Am J Nephrol. 1999;19:559–564. doi: 10.1159/000013520.
    1. Bessell JR, Proudman WD, Parkyn RF, Disney AP. Parathyroidectomy in the treatment of patients with chronic renal failure: a 10-year review. Br J Surg. 1993;80:40–42. doi: 10.1002/bjs.1800800114.
    1. Higgins RM, Richardson AJ, Ratcliffe PJ, Woods CG, Oliver DO, Morris PJ. Total parathyroidectomy alone or with autograft for renal hyperparathyroidism? Q J Med. 1991;79:323–332.
    1. Niederle B, Roka R, Horandner H. Recurrent renal hyperparathyroidism: reoperation on the autograft. Wien Klin Wochenschr. 1988;100:369–372.
    1. Walgenbach S, Hommel G, Bernhard G, Kohler H, Wandel E, Gohlke F, Junginger T. [Prospective observational study of surgical therapy of renal hyperparathyroidism] Chirurg. 1997;68:147–153. doi: 10.1007/s001040050165.
    1. Yumita S. Intervention for recurrent secondary hyperparathyroidism from a residual parathyroid gland. Nephrol Dial Transplant. 2003;18 Suppl 3:iii62–iii64.
    1. Patow CA, Norton JA, Brennan MF. Vocal cord paralysis and reoperative parathyroidectomy. A prospective study. Ann Surg. 1986;203:282–285. doi: 10.1097/00000658-198603000-00011.
    1. Kaye M, D'Amour P, Henderson J. Elective total parathyroidectomy without autotransplant in end-stage renal disease. Kidney Int. 1989;35:1390–1399. doi: 10.1038/ki.1989.138.
    1. Farrington K, Varghese Z, Chan MK, Fernando ON, Baillod RA, Sweny P, Moorhead JF. How complete is a total parathyroidectomy in uraemia? Br Med J (Clin Res Ed) 1987;294:743.
    1. Gasparri G, Camandona M, Abbona GC, Papotti M, Jeantet A, Radice E, Mullineris B, Dei PM. Secondary and tertiary hyperparathyroidism: causes of recurrent disease after 446 parathyroidectomies. Ann Surg. 2001;233:65–69. doi: 10.1097/00000658-200101000-00011.
    1. Saunders RN, Karoo R, Metcalfe MS, Nicholson ML. Four gland parathyroidectomy without reimplantation in patients with chronic renal failure. Postgrad Med J. 2005;81:255–258. doi: 10.1136/pgmj.2004.026450.
    1. Clark OH. Mediastinal parathyroid tumors. Arch Surg. 1988;123:1096–1100.
    1. Kaczirek K, Prager G, Kienast O, Dobrozemsky G, Dudczak R, Niederle B, Kurtaran A. Combined transmission and (99m)Tc-sestamibi emission tomography for localization of mediastinal parathyroid glands. Nuklearmedizin. 2003;42:220–223.
    1. Pattou FN, Pellissier LC, Noel C, Wambergue F, Huglo DG, Proye CA. Supernumerary parathyroid glands: frequency and surgical significance in treatment of renal hyperparathyroidism. World J Surg. 2000;24:1330–1334. doi: 10.1007/s002680010220.
    1. Summers GW. Parathyroid update: a review of 220 cases. Ear Nose Throat J. 1996;75:434–439.
    1. Schlosser K, Zielke A, Rothmund M. Medical and surgical treatment for secondary and tertiary hyperparathyroidism. Scand J Surg. 2004;93:288–297.
    1. Zaraca F, Mazzaferro S, Catarci M, Saputelli A, Alo P, Carboni M. Prospective evaluation of total parathyroidectomy and autotransplantation for the treatment of secondary hyperparathyroidism. Arch Surg. 1999;134:68–72. doi: 10.1001/archsurg.134.1.68.
    1. Walgenbach S, Hommel G, Junginger T. Prospective evaluation of parathyroid graft function after total parathyroidectomy and heterotopic autotransplantation in renal hyperparathyroidism by bilateral determination of intact parathormone in cubital venous blood. World J Surg. 1998;22:93–97. doi: 10.1007/s002689900355.
    1. Welk RA, Alix DR. A community hospital experience with total parathyroidectomy and autotransplantation for renal hyperparathyroidism. Am Surg. 1987;53:622–627.
    1. Chou FF, Lee CH, Chen HY, Chen JB, Hsu KT, Sheen-Chen SM. Persistent and recurrent hyperparathyroidism after total parathyroidectomy with autotransplantation. Ann Surg. 2002;235:99–104. doi: 10.1097/00000658-200201000-00013.
    1. Dotzenrath C, Cupisti K, Goretzki E, Mondry A, Vossough A, Grabensee B, Roher HD. Operative treatment of renal autonomous hyperparathyroidism: cause of persistent or recurrent disease in 304 patients. Langenbecks Arch Surg. 2003;387:348–354.
    1. Korzets Z, Magen H, Kraus L, Bernheim J, Bernheim J. Total parathyroidectomy with autotransplantation in haemodialysed patients with secondary hyperparathyroidism--should it be abandoned? Nephrol Dial Transplant. 1987;2:341–346.
    1. Kaye M, Rosenthall L, Hill RO, Tabah RJ. Long-term outcome following total parathyroidectomy in patients with end-stage renal disease. Clin Nephrol. 1993;39:192–197.
    1. Hampl H, Steinmuller T, Frohling P, Naoum C, Leder K, Stabell U, Schnoy N, Jehle PM. Long-term results of total parathyroidectomy without autotransplantation in patients with and without renal failure. Miner Electrolyte Metab. 1999;25:161–170. doi: 10.1159/000057440.
    1. Ljutic D, Cameron JS, Ogg CS, Turner C, Hicks JA, Owen WJ. Long-term follow-up after total parathyroidectomy without parathyroid reimplantation in chronic renal failure. QJM. 1994;87:685–692.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi